A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)
Summary
- Eligibility
- for people ages 4 years and up (full criteria)
- Location
- at UCSD
- Dates
- study startedcompletion around
- Principal Investigator
- by Chamindra Laverty, MD (ucsd)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Chamindra Laverty, MD (ucsd)
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Sarepta Therapeutics, Inc.
- ID
- NCT06246513
- Phase
- Phase 3 Limb-Girdle Muscular Dystrophy Research Study
- Study Type
- Interventional
- Participants
- Expecting 15 study participants
- Last Updated